HK1207004A1 - Treatment of mild and moderated alzheimer's disease - Google Patents

Treatment of mild and moderated alzheimer's disease Download PDF

Info

Publication number
HK1207004A1
HK1207004A1 HK15107776.8A HK15107776A HK1207004A1 HK 1207004 A1 HK1207004 A1 HK 1207004A1 HK 15107776 A HK15107776 A HK 15107776A HK 1207004 A1 HK1207004 A1 HK 1207004A1
Authority
HK
Hong Kong
Prior art keywords
day
subject
phenoxy
hydrochloride
achei
Prior art date
Application number
HK15107776.8A
Other languages
English (en)
Chinese (zh)
Inventor
．奧蘭迪
C.奥兰迪
．克拉克
D.J.克拉克
．格裡梅斯
I.M.格里梅斯
．瓦爾卡西-洛佩茲
M.C.瓦尔卡西-洛佩兹
．考斯圖拉
M.J.考斯图拉
Original Assignee
Vtv治疗有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv治疗有限责任公司 filed Critical Vtv治疗有限责任公司
Publication of HK1207004A1 publication Critical patent/HK1207004A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
HK15107776.8A 2012-10-05 2013-10-02 Treatment of mild and moderated alzheimer's disease HK1207004A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
US61/710,229 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK19132980.4A Addition HK40009571A (zh) 2012-10-05 2015-08-11 治疗轻度和中度阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
HK1207004A1 true HK1207004A1 (en) 2016-01-22

Family

ID=49354960

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107776.8A HK1207004A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderated alzheimer's disease

Country Status (16)

Country Link
US (3) US9717710B2 (enExample)
EP (1) EP2903606A1 (enExample)
JP (2) JP6566868B2 (enExample)
KR (1) KR20150064743A (enExample)
CN (2) CN104703592A (enExample)
AU (2) AU2013327450B2 (enExample)
BR (1) BR112015007641A8 (enExample)
CA (1) CA2886785C (enExample)
EA (1) EA201590687A1 (enExample)
HK (1) HK1207004A1 (enExample)
IL (1) IL237730B (enExample)
IN (1) IN2015DN03734A (enExample)
MX (1) MX377733B (enExample)
NZ (2) NZ705813A (enExample)
SG (2) SG11201502210VA (enExample)
WO (1) WO2014055588A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114957470B (zh) * 2021-11-12 2023-01-17 深圳市人民医院 靶向rage的纳米抗体及其应用
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
EP0352581A3 (de) 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
US5166214A (en) 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
ES2170104T3 (es) 1993-10-01 2002-08-01 Merrell Pharma Inc Inhibidores de la produccion de proteinas de beta-amiloide.
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5939526A (en) 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
EP1184370B1 (en) 1996-07-22 2005-09-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US5962535A (en) 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6274615B1 (en) 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
JP2003507013A (ja) 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CA2440042C (en) 2001-03-05 2011-09-27 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
JP2006522128A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
SI1703902T1 (sl) 2004-01-05 2011-02-28 Merz Pharma Gmbh & Co Kgaa Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni
DE102004050176A1 (de) 2004-09-20 2006-03-23 Universität Duisburg-Essen Optoelektronisches Bauelement und Verfahren zum Steuern von Tunnelelektronenströmen durch Photonen
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ，インコーポレイテッド ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
BRPI1012697A2 (pt) 2009-04-27 2016-03-29 High Point Pharmaceuticals Llc derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2012061927A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
US20170326113A1 (en) 2017-11-16
CN104703592A (zh) 2015-06-10
CA2886785C (en) 2022-06-07
MX2015003732A (es) 2015-09-23
MX377733B (es) 2025-03-11
JP2015535850A (ja) 2015-12-17
BR112015007641A8 (pt) 2018-04-03
CA2886785A1 (en) 2014-04-10
JP6566868B2 (ja) 2019-08-28
AU2013327450B2 (en) 2018-07-12
IN2015DN03734A (enExample) 2015-09-18
JP6894940B2 (ja) 2021-06-30
EP2903606A1 (en) 2015-08-12
BR112015007641A2 (pt) 2017-07-04
US20140100218A1 (en) 2014-04-10
US20190142803A1 (en) 2019-05-16
WO2014055588A1 (en) 2014-04-10
JP2019163301A (ja) 2019-09-26
AU2018203434A1 (en) 2018-06-07
CN110292638A (zh) 2019-10-01
KR20150064743A (ko) 2015-06-11
NZ739521A (en) 2019-06-28
AU2013327450A1 (en) 2015-05-14
NZ705813A (en) 2018-02-23
IL237730B (en) 2018-10-31
EA201590687A1 (ru) 2015-09-30
US9717710B2 (en) 2017-08-01
SG11201502210VA (en) 2015-04-29
SG10201702648YA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
JP2019163301A (ja) 軽度および中等度アルツハイマー病の処置
Chen et al. Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
US20220040126A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
JP2026035578A (ja) ファブリー病の治療用投薬レジメン
AU2006226811B2 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
EP3607942B1 (en) Medicament and method of diagnosis
Lubanda et al. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
Kang et al. Xuebijing injection protects sepsis induced myocardial injury by mediating TLR4/NF-κB/IKKα and JAK2/STAT3 signaling pathways
Dahl et al. Safety and tolerability of once-daily tiotropium Respimat® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis
US20210113495A1 (en) Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
EP4599894A2 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
Billin et al. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury
Pisanu et al. Modulation of Δ9-THC-induced increase of cortical and hippocampal acetylcholine release by μ opioid and D1 dopamine receptors
Li et al. Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis
Lo et al. Long-term cardiovascular, renal, and safety outcomes of teprotumumab versus systemic glucocorticoids in thyroid eye disease: a target trial emulation
Deyneli et al. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients
Zhao et al. Effect of Shenfu injection on porcine renal function after cardiopulmonary resuscitation
HK40009571A (zh) 治疗轻度和中度阿尔茨海默病的方法
WO2018006051A1 (en) Diagnostic or predictor of relapsing remitting multiple sclerosis
Abdalwahab et al. Characteristics and outcome of acute clozapine intoxicated patients with special consideration to its cardiac manifestations
HK40126655A (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
Zaremba-Pechmann et al. Ronald Dahl, Michael Engel b, Daniel Dusser c, David Halpin d, Huib AM Kerstjens e
Clough et al. Effect of inflammatory mediators on the developing micro circulation of the rabbit ear chamber
Gupta et al. POTENTIAL TARGETS FOR EFFECTIVE THERAPEUTIC INTERVENTION FOR THE TREATMENT OF DIABETIC NEPHROPATHY